MOC31PE immunotoxin – targeting peritoneal metastasis from epithelial ovarian cancer

Yvonne Andersson; Synne Ihler Haavardtun; Ben Davidson; Anne Dorum; Karianne G. Fleten; Oystein Fodstad; Kjersti Flatmark

doi:10.18632/oncotarget.18694

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Research Papers:

MOC31PE immunotoxin – targeting peritoneal metastasis from epithelial ovarian cancer

Yvonne Andersson _, Synne Ihler Haavardtun, Ben Davidson, Anne Dorum, Karianne G. Fleten, Oystein Fodstad and Kjersti Flatmark

PDF | HTML | Supplementary Files | How to cite

Oncotarget. 2017; 8:61800-61809. https://doi.org/10.18632/oncotarget.18694

Metrics: PDF 1865 views | HTML 2498 views | ?

Abstract

Yvonne Andersson1, Synne Ihler Haavardtun1,5, Ben Davidson2,5, Anne Dørum3, Karianne G. Fleten1,5, Øystein Fodstad1,5 and Kjersti Flatmark1,4,5

1Department of Tumor Biology, Norwegian Radium Hospital, Oslo University Hospital, 0424 Oslo, Norway

2Department of Pathology, Norwegian Radium Hospital, Oslo University Hospital, 0424 Oslo, Norway

3Department of Gynecologic Oncology, Norwegian Radium Hospital, Oslo University Hospital, 0424 Oslo, Norway

4Department of Gastroenterological Surgery, Norwegian Radium Hospital, Oslo University Hospital, 0424 Oslo, Norway

5Institute of Clinical Medicine, University of Oslo, 0310 Oslo, Norway

Correspondence to:

Yvonne Andersson, email: [email protected]

Keywords: MOC31PE immunotoxin, EpCAM, peritoneal metastasis of epithelial ovarian cancer, chemotherapy, animal models

Received: December 06, 2016 Accepted: May 15, 2017 Published: June 27, 2017

ABSTRACT

Peritoneal metastasis (PM) is an important feature of epithelial ovarian cancer (EOC) and is a frequent site of drug resistant disease recurrence, identifying PM-EOC an important clinical challenge. The MOC31PE immunotoxin targets and kills tumor cells expressing the epithelial cell adhesion molecule (EpCAM), which is highly expressed in EOC, and MOC31PE is being investigated for use in treatment of PM-EOC.

The efficacy of MOC31PE treatment alone and in combination with cytotoxic drugs was investigated in two human EpCAM expressing EOC cell lines, B76 and MDHA-2774, in vitro and in corresponding mouse models mimicking PM-EOC. MOC31PE efficaciously killed tumor cells alone and showed equal or superior activity in vitro (paclitaxel, cisplatin, carboplatin) and in vivo (paclitaxel, mitomycin C) compared to the investigated cytotoxic drugs. Additive, or importantly, no antagonistic effects were observed in combination experiments.

In ex vivo cell culture, the cytotoxic effect of MOC31PE was studied on freshly isolated surgical EOC samples. All investigated fresh EOC samples expressed EpCAM and MOC31PE effectively reduced cell viability in ex vivo cultures.

In conclusion, these results, together with our previous preclinical and clinical experience, support development of MOC31PE for treatment of PM-EOC in combination with currently used cytotoxic drugs.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 18694

Publication Alerts

Research Papers:

MOC31PE immunotoxin – targeting peritoneal metastasis from epithelial ovarian cancer

Abstract